ELTX
Elicio Therapeutics Inc (ELTX)
Healthcare • NASDAQ • $4.11-0.72%
- Symbol
- ELTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $4.11
- Daily Change
- -0.72%
- Market Cap
- $73.48M
- Trailing P/E
- N/A
- Forward P/E
- -1.46
- 52W High
- $16.00
- 52W Low
- $2.66
- Analyst Target
- $20.67
- Dividend Yield
- N/A
- Beta
- N/A
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Company websiteResearch ELTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.